1 May 2020

Following positive results from a NIAID-led trial of remdesivir, Gilead Sciences is expanding the production of its investigational drug for Covid-19. The company aims to manufacture more than 140,000 treatment courses of remdesivir by the end of this month, which will rise to more than one million treatment courses by the end of the year.

Glenmark Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) to evaluate antivirial drug favipiravir in clinical trials to treat patients with Covid-19. Favipiravir is a generic version of Fujifilm Toyama Chemical‘s influenza drug Avigan. Glenmark developed the drug’s API and formulations internally.

Inovio Pharmaceuticals has entered a manufacturing alliance with German contract manufacturer Richter-Helm BioLogics for large-scale production of its DNA vaccine candidate, INO-4800, against Covid-19. The deal is partly supported by an initial grant of $1.3m from the Coalition for Epidemic Preparedness Innovations (CEPI).

Researchers from University of California San Diego School of Medicine have initiated a clinical trial to study hypertension drug Ramipril as a potential Covid-19 treatment. Ramipril, an ACE inhibitor, will be evaluated in up to 560 patients with Covid-19 symptoms at emergency departments or hospitalised due to the infection.

Pfizer has plans to rapidly boost manufacturing of Covid-19 vaccine candidate to approximately ten to 20 million doses by the end of this year for emergency use, if it demonstrates safety and efficacy in the coming months, reported Reuters. Being developed in alliance with BioNtech, the vaccine candidate is currently in a clinical trial in Germany and a study in the US is expected to begin soon.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.